Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 15/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 10/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955356 | 0.87 | PIK3CB (0.59) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL995224 | 0.86 | PIK3CA (0.65) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL949619 | 0.85 | PIK3CB (0.66) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL477273 | 0.83 | PIK3CA (0.68) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL1083283 | 0.83 | PIK3CB (0.56) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL995140 | 0.83 | PIK3CB (0.59) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL996060 | 0.83 | PIK3CB (0.60) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL951269 | 0.80 | PIK3CB (0.58) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL900032 | 0.80 | PIK3CA (0.66) | PIK3CBPIK3CAPIK3CDPIK3R1 | |
| SCHEMBL477649 | 0.78 | PIK3CD (0.67) | PIK3CBPIK3CAPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-8486939-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | PATHWAY THERAPEUTICS INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2532659-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | Pathway Therapeutics, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009405-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES AND THEIR USE IN CANCER THERAPY | TYMP, TYMS, CCNI | PIK3CB 397/4885PIK3CA 187/4885PIK3CD 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.